Kees van Bergen
Kees van Bergen
Leiden University Medical Center
Zweryfikowany adres z ziggo.nl - Strona główna
Tytuł
Cytowane przez
Cytowane przez
Rok
Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
JHF Falkenburg, AR Wafelman, P Joosten, WM Smit, CAM van Bergen, ...
Blood, The Journal of the American Society of Hematology 94 (4), 1201-1208, 1999
3441999
Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells
WM Smit, M Rijnbeek, CAM van Bergen, RA de Paus, HAW Vervenne, ...
Human immunology 53 (2), 216-223, 1997
1071997
High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning
CAM Van Bergen, CE Rutten, ED Van Der Meijden, ...
Cancer research 70 (22), 9073-9083, 2010
1062010
Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene
CAM van Bergen, MGD Kester, I Jedema, MHM Heemskerk, ...
Blood 109 (9), 4089-4096, 2007
1032007
T cells recognizing leukemic CD34+ progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem …
WM Smit, M Rijnbeek, CAM Van Bergen, WE Fibbe, R Willemze, ...
Proceedings of the National Academy of Sciences 95 (17), 10152-10157, 1998
961998
Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity
AN Stumpf, ED van der Meijden, CAM van Bergen, R Willemze, ...
Blood, The Journal of the American Society of Hematology 114 (17), 3684-3692, 2009
802009
HLA class II upregulation during viral infection leads to HLA-DP–directed graft-versus-host disease after CD4+ donor lymphocyte infusion
S Stevanović, CAM van Bergen, SAP van Luxemburg-Heijs, ...
Blood, The Journal of the American Society of Hematology 122 (11), 1963-1973, 2013
702013
Autosomal minor histocompatibility antigens: how genetic variants create diversity in immune targets
M Griffioen, CAM van Bergen, JH Falkenburg
Frontiers in immunology 7, 100, 2016
632016
Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific
AL Amir, DM van der Steen, RS Hagedoorn, MGD Kester, ...
Blood, The Journal of the American Society of Hematology 118 (26), 6733-6742, 2011
592011
Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma
D Schneider, M Dühren-von Minden, A Alkhatib, C Setz, CAM van Bergen, ...
Blood 125 (21), 3287-3296, 2015
572015
Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem …
E Marijt, A Wafelman, M van der Hoorn, C van Bergen, R Bongaerts, ...
haematologica 92 (1), 72-80, 2007
522007
Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
CAM van Bergen, SAP van Luxemburg-Heijs, LC de Wreede, M Eefting, ...
The Journal of clinical investigation 127 (2), 517-529, 2017
512017
Patient HLA-DP–Specific CD4+ T Cells from HLA-DPB1–Mismatched Donor Lymphocyte Infusion Can Induce Graft-versus-Leukemia Reactivity in the Presence or Absence of Graft-versus …
CE Rutten, SAP van Luxemburg-Heijs, CJM Halkes, CAM van Bergen, ...
Biology of Blood and Marrow Transplantation 19 (1), 40-48, 2013
512013
Generation of leukemia-reactive cytotoxic T lymphocytes from HLA-identical donors of patients with chronic myeloid leukemia using modifications of a limiting dilution assay
WM Smit, M Rijnbeek, CAM Van Bergen, R Willemze, JHF Falkenburg
Bone marrow transplantation 21 (6), 553-560, 1998
411998
Identification of 4 novel HLA-B* 40: 01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity
M Griffioen, MW Honders, ED van der Meijden, SAP van Luxemburg-Heijs, ...
Haematologica 97 (8), 1196, 2012
382012
Proteosomal degradation of BCR/ABL protein can generate an HLA-A* 0301-restricted peptide, but high-avidity T cells recognizing this leukemia-specific antigen were not demonstrated
EF Posthuma, CA Van Bergen, MG Kester, RA de Paus, PA van Veelen, ...
haematologica 89 (9), 1062-1071, 2004
362004
Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach
P Hombrink, C Hassan, MGD Kester, AH de Ru, CAM van Bergen, ...
The Journal of Immunology 190 (8), 3869-3877, 2013
352013
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation
CHJ Lamers, R Wijers, CAM van Bergen, JAE Somers, E Braakman, ...
Blood 128 (17), 2165-2174, 2016
272016
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data
PM Armistead, S Liang, H Li, S Lu, CAM Van Bergen, G Alatrash, LS John, ...
PloS one 6 (8), e23217, 2011
232011
Identification of biological relevant minor histocompatibility antigens within the B-lymphocyte–derived HLA-ligandome using a reverse immunology approach
P Hombrink, C Hassan, MGD Kester, L Jahn, MJ Pont, AH de Ru, ...
Clinical Cancer Research 21 (9), 2177-2186, 2015
222015
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20